Combined Therapeutics
June 23, 2026
Theater 3
Type: Company Presentation
Focus Area:
Multiple Therapeutics
Combined is developing MOP (Muli-Organ Protection), an mRNA translation-cell selective platform designed to reduce off-target expression and make (mRNA) medicines safer and more effective. Combined Tx is approaching a key inflection point: We are advancing IL-12-MOP into Phase 1 with NIH grant and Harvard/Boston Children’s Hospital and Brigham and Women's Hospital, while seeing growing inbound interest in our MOP platform for cancer vaccines, in vivo CAR-T/M, and other immuno-oncology applications. The platform has been featured in Nature, published in Science Translational Medicine, supported by humoral and cellular NHP data, and backed by granted IP, including in cancer vaccines and adjuvants.
Company HQ City:
Boston
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2016
Lead Product in Development:
IL12 MOP
CEO
Romain Micol
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
5
When you expect your next catalyst update?
9 months
What is your next catalyst (value inflection) update?
Our near-term focus is on: IL-12-MOP entering Phase 1 (as adjuvant notably for cancer therapies), GM-CSF-MOP moving from NHP to Ph1, expansion into in vivo CAR-T/M
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}